Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
Status:
Completed
Trial end date:
2018-03-15
Target enrollment:
Participant gender:
Summary
It is not uncommon that patients requiring dual antiplatelet therapy (DAPT) also need to be
treated with oral anticoagulant therapy, such as those with atrial fibrillation (AF).
Warfarin and clopidogrel are still the most widely utilized oral anticoagulant and P2Y12
receptor inhibitor, respectively. However, over the past years, several non-vitamin K
antagonist oral anticoagulants, including edoxaban, have been studied in the setting of AF
showing encouraging safety and efficacy profiles as compared with warfarin. However, the
effects of edoxaban in combination with DAPT in the setting of patients with coronary artery
disease (CAD) are unexplored. Moreover, the role of edoxaban as part of a dual antithrombotic
treatment strategy, including clopidogrel and stopping aspirin, represents another important
area of clinical interest. This investigation is a prospective, randomized, parallel-design,
open label, pharmacodynamic study conducted in patients with CAD on DAPT with aspirin and
clopidogrel testing two different edoxaban dosing regimens in addition to DAPT with aspirin
and clopidogrel, as well as in combination with clopidogrel only (after stopping aspirin).